Shanghai RAAS Blood Products 2025 Net Profit Down 28.1%
· Issued by Shanghai RAAS Blood Products Co., Ltd.
Shanghai RAAS Blood Products Co Ltd SZSE:002252:
Shanghai RAAS Blood Products Co., Ltd. on 6ix
Earlier from Shanghai RAAS Blood Products
- Shanghai RAAS Blood Products: Net profit dropped 26% on flat revenue, with major buybacks and clinical trial advances
- Shanghai RAAS Blood Products Q3 Net Profit Down 26.2% Y/Y
- Shanghai RAAS Blood Products: Revenue and profit fell, but cash flow and strategic expansion strengthened future prospects
- Shanghai RAAS Blood Products: Net profit fell 25% in Q1 2025, but strategic acquisitions and buybacks support future growth
- Shanghai RAAS Blood Products: 2024 saw robust profit growth, Haier control, and strategic expansion for Shanghai RAAS
Later from Shanghai RAAS Blood Products
All Shanghai RAAS Blood Products news releases↗